2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis

Abstract

The objective of this document is to provide a comprehensive update of the recommendations of Brazilian Society of Rheumatology on drug treatment of rheumatoid arthritis (RA), based on a systematic literature review and on the opinion of a panel of rheumatologists. Four general principles and eleven recommendations were approved. General principles: RA treatment should (1) preferably consist of a multidisciplinary approach coordinated by a rheumatologist, (2) include counseling on lifestyle habits, strict control of comorbidities, and updates of the vaccination record, (3) be based on decisions shared by the patient and the physician after clarification about the disease and the available therapeutic options; (4) the goal is sustained clinical remission or, when this is not feasible, low disease activity. Recommendations: (1) the first line of treatment should be a csDMARD, started as soon as the diagnosis of RA is established; (2) methotrexate (MTX) is the first-choice csDMARD; (3) the combination of two or more csDMARDs, including MTX, may be used as the first line of treatment; (4) after failure of first-line therapy with MTX, the therapeutic strategies include combining MTX with another csDMARD (leflunomide), with two csDMARDs (hydroxychloroquine and sulfasalazine), or switching MTX for another csDMARD (leflunomide or sulfasalazine) alone; (5) after failure of two schemes with csDMARDs, a bDMARD may be preferably used or, alternatively a tsDMARD, preferably combined, in both cases, with a csDMARD; (6) the different bDMARDs in combination with MTX have similar efficacy, and therefore, the therapeutic choice should take into account the peculiarities of each drug in terms of safety and cost; (7) the combination of a bDMARD and MTX is preferred over the use of a bDMARD alone; (8) in case of failure of an initial treatment scheme with a bDMARD, a scheme with another bDMARD can be used; in cases of failure with a TNFi, a second bDMARD of the same class or with another mechanism of action is effective and safe; (9) tofacitinib can be used to treat RA after failure of bDMARD; (10) corticosteroids, preferably at low doses for the shortest possible time, should be considered during periods of disease activity, and the risk-benefit ratio should also be considered; (11) reducing or spacing out bDMARD doses is possible in patients in sustained remission.

Disability retirement among university public servants: epidemiological profile and causes

“…It is noted in the present investigation that the frequency of comorbidities also contributed to the disability pensions, since they were consequences of health problems presented by the interviewees, that is to say, it was possible to identify the existence of other diseases besides those that cause disability in the retired, even the vast majority of participants self-report making continuous use of medications. The highest frequency of NCD among females was also identified in a population survey conducted in Brazil in 2013 (36) ; however, the higher frequency of arthritis among men found in this study is contrary to the literature, which reports a higher prevalence among women (37) . The results of this study confirm the impact of NCD on disability pensions and the need for programs to improve workers' health as measures to identify the risk factors for chronic diseases, in order to awaken the worker to harmful habits.…”

Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study

“…Current standards of care in RA incorporate these concepts and postulate a rational stepwise approach to the pharmacological treatment of the disease [5][6][7]. Although widely accepted by rheumatologists, T2T implementation and its actual benefits in day-to-day clinical practice are still not well established [8].…”

Systematic Review of Recommendations on the Use of Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer

“…The risk of cancer associated with the use of specific DMARDs was noted as controversial and inconclusive. However, 19 recommendations attributed an increased risk for at least 1 type of cancer to at least 1 agent (5,6,11,12,14,15,17,19,24,25,(28)(29)(30)32,33,37,38,40,41).…”